ALK | Allergy solutions for life
ALK

Celebrating the past and future of allergy solutions for life

Front_page_1
Front_page_2

Pioneers in helping people with allergies

For 100 years, ALK has consistently devised and developed major advances for the treatment of allergy

News

  • Post date
    02/16/2024
    Annual General Meeting in ALK-Abelló A/S on 14 March 2024
  • Post date
    02/12/2024
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    02/12/2024
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    02/08/2024
    Annual report 2023: ALK delivers 9% sales growth with profits up 50%
  • Post date
    02/07/2024
    ALK and McMaster researchers discover new cell that remembers allergies
  • Post date
    02/05/2024
    ALK’s 2030 CO2 reduction targets have been approved by SBTi
  • Post date
    01/31/2024
    Release date of annual report 2023 for ALK and webcast
  • Post date
    01/25/2024
    ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review
  • Post date
    01/18/2024
    ALK completes first part of phase 1 trial with peanut SLIT-tablet
100 Years of Pioneering Allergy Solutions
A new book has been written about ALK’s fascinating development in the field of allergy
The hunt for a vaccine – a podcast in five episodes
A fascinating story about ALK and the company’s 100 years of hunting allergy vaccines have been turned into a captivating podcast.
Investigator-initiated clinical trials in allergy immunotherapy
The call for applications is now open!
Strategy update: Focus areas during 2021-23
Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.